Administration of anandamide (AEA) or 2-arachidonoylglycerol (2AG) induces CB1 coupling and activation of TRKB receptors, regulating the neuronal migration and maturation in the developing cortex.
Introduction
Repetitive behaviors are part of the normal background of animal's learning 1, 2 . These stereotypic motor procedures are regulated by the cortical-striatal-thalamo-cortical (CSTC) circuitry, a series of multiple reverberatory loops, with the prefrontal cortex, striatum and thalamic nuclei playing a core role as integrative hubs 3 . Changes in the CSTC can trigger abnormal repetitive behaviors. These aberrant behaviors can be related to several human neuropsychiatric conditions such as Huntington's disease and obsessive-compulsive disorder (OCD). In a simplified version, the CSTC is divided into two major pathways: direct and indirect 4 . The direct pathway comprises the cortical projections to globus pallidus ( pars internalis ) and substantia nigra pars reticulata, while the indirect pathway engages a more complex set of relay structures, involving the globus pallidus pars externalis and subthalamic nucleus -(for review see Canales et al. 2000 5 ) . The resultant activity between these two pathways regulates the output of the basal ganglia in favor of one of the two possible effects: increase in the repetitive movements (favored by the direct pathway activity) or inhibition of such programs, a consequence of activation of the indirect pathway. Although highly simplified, this model of the CSTC circuit provides a useful framework for understanding circuit physiology and putative dysfunctions 4 .
Multiple neurotransmitters/neuromodulators systems act in coordination to regulate the balance in the CSTC circuitry. Among them, endocannabinoids play a central role regulating not only glutamatergic, but also GABAergic, serotonergic, and dopaminergic transmission (for review see López-Moreno et al.
2008 6 ). Briefly, the activation of CB1 receptors by AEA (N-arachidonoylethanolamine) or 2-AG (2-arachidonoylglycerol), produced as 'on-demand retrograde messengers', decreases the activity of presynaptic neurons via Gi/0 and modulation of calcium and potassium channels [for review see Chevaleyre et al. 2006 7 ]. Due to these effects, endocannabinoids are putatively able to regulate excessive neurotransmission in the CSTC system. Besides, the synthesis and release of endocannabinoids usually is triggered by depolarization-induced calcium influx, as well as by activated phospholipase-C-beta following activation of Gq-protein coupled receptors 8, 9 .
Endocannabinoids can also act on TRPV1 receptors. These receptors increase calcium influx, facilitating a rapid depolarization of the neuronal cells 10, 11 . In preclinical anxiety models, high doses of AEA are usually ineffective or cause anxiogenic rather than anxiolytic effects. This bell-shaped dose-effect curve has been associated with TRPV1 activation and is reversed by pretreatment with antagonists of these receptors 10 (for review see Moreira and Wotjak, 2010; Aguiar et al. 2014 12, 13 ).
Accordingly, the anxiolytic effect of capsaicin, an agonist of TRPV1 receptors, observed after intracerebral administration was attributed to a desensitization of the channels 14 .
CB1 receptors are highly expressed in the anterior cingulate cortex, striatum and substantia nigra 15, 16 , major hubs of CSTC circuitry. TRPV1 has a less broad expression when compared to CB1 17, 18 .
However, these two receptors are colocalized in the periaqueductal grey matter (PAG) and prefrontal cortex 10, 19 , playing opposite functional roles.
CB1 receptors can couple to and transactivate tyrosine kinase receptors 20 , including the tropomyosin-related kinase B -TRKB 21 . TRKB is the receptor of brain-derived neurotrophic factor (BDNF), a member of the neurotrophic family that includes NGF, NT-3 and NT4/5 22 . The activation of TRKB is a crucial factor in the regulation of brain plasticity 23 . Animals lacking CB1 receptors (CB1.KO) display behavioral despair and a reduction in BDNF levels in hippocampus 24 , suggesting an interplay between these two systems during development and in adulthood. CB1.KO animals also exhibit impaired extinction of aversive memories 25 , a feature usually facilitated by the activation of TRKB following antidepressant treatment, and prevented by reduced BDNF expression 26 .
Thus, the initial aim of the present study was to investigate if CB1 and TRKB systems interact in a mouse model of anxiety/repetitive behavior, trying to replicate the in vitro mechanism proposed by Berghuis and colleagues 21 . Following the results obtained in the present study, we then speculate on the participation of TRPV1 in the AEA effects on TRKB. 
Material and methods

Animals
Primary cultures.
Cortex of E18 rat embryos were dissected and the cells plated in poly-L-lysine coated wells at a 0.5x10 6 cells/ml density in Neurobasal medium 27 . The cells were left undisturbed, except for medium change, for 8 days before drug treatment and sample collection.
Apparatus and procedure
Marble burying test (MBT). Test was performed using a square box (30x20x12cm) with 5cm sawdust layer covered floor. Twelve green clear glass marbles (1.5cm in diameter) were evenly spaced over the floor. One hour before test the animals were left undisturbed in the experimental room. Mice were initially placed on the box´s center containing marbles. Twenty-five min later they were taken from the box, and the number of buried marbles was counted. Criteria for buried marbles included only those with at least two-thirds under sawdust 28 .
Locomotor activity. Male mice were submitted to a 25min session in a circular arena (40cm in diameter with a 50cm high plexiglass wall). Each session was videotaped, and the total activity (distance travelled by the mice in meters) was analyzed with the help of the Anymaze software (version 4.5, Stoelting, Ireland). The apparatus was previously cleaned with 70% alcohol solution before each animal assessment.
Stereotaxic surgery. Briefly, male mice were anesthetized with tribromoethanol and fixed in a stereotaxic frame. Next, stainless steel guide cannulas (0.7mm OD, 9mm length) were implanted into the prelimbic ventromedial prefrontal cortex (PL; coordinates: AP= -2.8mm from bregma, L= 1.5mm, DV= 2mm; lateral inclination of 20°) and then attached to skull bone with steel screws and acrylic cement.
Obstruction was prevented with a stylet inside guide cannula. About five days after surgical procedure, bilateral intracerebral infusions in a volume of 200nl were performed with a dental needle (0.3mm OD) during 1min. Hamilton micro-syringe (Sigma-Aldrich) and an infusion pump (KD Scientific) were used.
Following the behavioral tests, mice were anesthetized with chloral hydrate and 200nL of methylene blue was infused 1.5mm deeper than the guide cannulas end. Brains were withdrawn and the injection sites verified. Data obtained from injections outside the aimed area were discarded. Coordinates for stereotaxic surgery and the histological location of the injections represented in figure 5 are based on the Paxinos' mouse brain atlas 29 . under CC-BY license 34 . difference between vehicle-and 20ng/ml-or 50ng/ml-treated groups (Fisher, p<0.0001 for both; figure   1c ). As seen in figure 1d, TRPV1 (VR1: band at 100kDa) was detected in samples from primary cultures after precipitation of CB1 or TRKB, the ratio of CB1-and TRKB-coupled TRPV1 compared to total TRPV1 were: 27.0% and 13.2%, respectively. 
Results
In vitro dose-response effects of AEA, CPS, and BDNF on TRKB phosphorylation
Effect of systemic and PFC local drug administration
As seen in figure 3a, two-way ANOVA indicates a significant interaction between drug treatments 
Immunolabeling of CB1, TRPV1, and CaMK2 or TRKB
As observed in figure 4a -c, the majority of TRPV1+ cells are also CaMK2+, while CB1 positive labels surround CaMK2+ cells, figure 4d-f. Figure 5 , depicts the triple labeling of TRPV, CB1 and TRKB.
Again, the majority of TRPV1+ cells were also positive for TRKB. 
Discussion
In the present study we described a coordinated activation of TRKB (pTRK) by AEA in a CB1and TRPV1-dependent manner. Lower doses of AEA administered to cultured cortical cells were able to increase pTRK levels through CB1 activation. On the other hand, our pharmacological approach has led us to suggest that BDNF effect on pTRK levels does not engage endocannabinoids production, at least in the timeframe used in the present study. Higher doses of AEA increased the pTRK levels in a TRPV1-dependent manner, an effect mimicked by capsaicin (CPS). Both AEA (at 200nM) and CPS required BDNF release to increase pTRK levels. However, CB1 and TRPV1 agonists, infused into PL-PFC produced opposite effects on burying behavior. CB1 agonist ACEA decreased, and TRPV1
agonist CPS increased the number of buried marbles. Further, BDNF infused into PL-PFC mimicked the behavioral effect of TRPV1 agonist. Data from total distance traveled indicates that the effects observed in the burying behavior could not be confounded by changes in locomotion.
Endocannabinoids (eCBs) exert multiple effects both at cellular and behavioral levels 35 . These molecules usually act as 'on-demand' retrograde messengers, following the activation of glutamatergic or gabaergic receptors in the postsynaptic terminal. Activation of CB1 receptors by eCBs increases the presynaptic terminal permeability to potassium while reducing calcium influx. As a result, the presynaptic terminal is hyperpolarized and the neurotransmission blunted 36 . On the other hand, higher concentrations of eCB also act on vanilloid receptor TRPV1 37 . Given that TRPV1 is a ligand-gated calcium channel, its activation by eCB increases the calcium permeability in the presynaptic terminal, therefore counteracting the activation of CB1 37 . Indeed, the behavioral data available indicates that in most cases eCB exhibit a bell-shaped curve, with lower concentrations acting mainly through CB1 and higher quantities exerting its effects through TRPV1 19 .
Previous studies indicate that, upon activation by AEA or 2AG, CB1 can couple to TRKB, and triggers its activity, underlying the maturation of cortical neurons 21 . The observed CB1:TRKB coupling did not involve the increase of BDNF production, both at translation or transcription level. In line with these findings, we observed that AEA administration in cultured cortical cells of rat embryo was indeed able to increase the levels of pTRK in a CB1-dependent manner. To verify other possible aspects of CB1:TRKB interaction, we tested if activation of TRKB by BDNF requires previous activation of CB1 or it is, at least partially, dependent on eCB production. Thereby, we found that TRKB activation by BDNF in our experimental conditions (cultivated embryonic cortical cells) did not demand any level of CB1 activation. On the other hand, in preparations of cerebellar granule neurons, the activation of TRKB by BDNF increased the neuronal sensitivity to eCB by increasing CB1 and decreasing the expression of the degrading enzyme monoacylglycerol lipase 38 . Other studies, using preparations of somatosensory cortex, suggest that GABAergic synapses are inhibited by a TRKB/PLCgamma1-dependent production of eCB from the postsynaptic pyramidal cell [39] [40] [41] . Finally, the probability of glutamate release in somatosensory cortex is decreased by BDNF/TRKB-induced eCB release 42 ; and eCBs are suggested to be produced and released to act also on midbrain dopamine neurons via previous activation of TRKB/PLC-gamma1 signaling 43 . Moreover, in organotypic hippocampal slice cultures, BDNF is a key downstream intermediary in CB1 protection against kainic acid-dependent excitotoxicity 44 . Thus, as previously described, TRKB activity modulates eCBs levels and the sensitivity of CB1 in response to eCB binding.
Then, both eCBs and BDNF can modulate each other but, concerning the direct activation of TRKB, a 'hierarchical' relationship between these two receptors is established.
The higher dose of AEA was more effective to increase the levels of pTRK through a TRPV1-dependent mechanism. Confirming this observation, CPS administration also increased pTRK levels in the same system. Our data suggest that AEA acts through TRPV1 receptors to release BDNF and increase pTRK levels. Interestingly, the levels of pTRK were decreased from 325% to 200% above the control levels (same level reached with AEA 100nM) in cells treated with AEA 200nM following the TRPV1 antagonist capsazepine or TRKB.Fc. Therefore, even if AEA has a higher affinity for CB1 than for TRPV1, the related efficacy appears to be inverted in favor of TRPV1. Thus, it is plausible that lower doses of eCB could induce modest activation of TRKB via CB1 coupling whereas higher doses, acting in both receptors CB1 and TRPV1, would boost BDNF release and pTRK levels. Accordingly, after treatment with AEA 200nM a positive correlation was observed between levels of BDNF released in culture medium and cellular levels of pTRK, thus corroborating the proposal that pTRK levels is increased by BDNF released, possibly in a TRPV1-dependent manner.
Next, we used the marble burying test (MBT) to further investigate in vivo the relevancy of BDNF/TRK modulation by CB1 and TRPV1. This test was initially proposed as a model of neophobic anxiety 28 , being sensitive to a variety of antidepressants, anxiolytics and antipsychotics 45, 46 . However, this proposal has been questioned by recent studies -for more detailed information see Thomas et al.
2009 47 . The burying behavior seems to reflect natural motor programs presented in the CSTC circuitry, rather than a novelty-induced anxious state. In accordance with prior data described by our group 48 , mice systemically treated with the CB1 agonist WIN display a reduced burying behavior. Such effect of WIN was counteracted by the previous administration of AM251 (a CB1 antagonist); and, in the present study, by the TRK blocker k252a. Therefore, as suggested by in vitro results, in vivo data supports BDNF/TRKB signaling as a downstream trigger of CB1-induced behavioral changes.
In this scenario, given that the PFC is one of the major hubs of CSTC regulation of the burying behavior, we tested the effects of CB1, TRKB and TRPV1 activation in this structure. Our data indicates that ACEA administration into PFC decreases the number of buried marbles. Surprisingly, the infusion of BDNF into PL-PFC increased the number of marbles buried. A similar facilitatory effect was also observed with CPS, and both ACEA and CPS effects were blocked by previous administration of k252a.
Opposed behavioral effects are usually observed when, after increasing concentrations of AEA, there is a target displacement from preferential CB1 to TRPV1 signaling. For example, whereas CB1 is usually responsible for the anxiolytic-like effect of low AEA doses, the activation of TRPV1 signaling by higher doses is associated with null or even anxiogenic-like effect 10, 19 . Thus, our behavioral results suggest that in the PL-PFC BDNF and TRPV1 play a similar role.
Taken together, our results indicate that in the PL-PFC, upon activation CB1 couples to TRKB in a BDNF-independent manner (as suggested by Berghuis and colleagues) to induce a modest increase of pTRK levels and an anticompulsive-like effect. TRPV1 activation by high AEA concentrations further boosts BDNF release counteracting the CB1-mediated effect. Exogenous BDNF administration, by producing high local concentrations of this growth factor, would mimic the effects observed after TRPV1 activation. One possible explanation for these results would be the existence of two distinct populations of neurons in the PL-PFC that colocalize TRKB:CB1 and TRKB:TRPV1, modulating the direct and indirect pathways of the CSTC circuitry, respectively. The second possibility is that the CB1-and TRPV1-dependent activation of TRKB occurs in pre and postsynaptic neurons, respectively. In this scenario, CB1 and TRPV1 would play opposed effects in the same pathway of the CSTC. These two scenarios, however, are not mutually exclusive. In agreement with this proposal, we observed a low level, although non-negligible, of co-immunoprecipitation between TRPV1 and TRKB or CB1. TRPV1, CB1, and TRKB immunolabeling in the PL-PFC slices indicate a partial overlap of these three receptors. The majority of the cells in the PL-PFC slices were double-positive to TRPV1/CaMK2, while CB1 surrounds CaMK2+ cells.
In addition, both CB1 and TRKB are mutually expressed in cortical layers 2/3 and 5 42 . CB1 receptors are also found in different neuronal populations. For instance, Marsicano and Lutz 49 observed that nearly all CB1 positive cells in multiple cortical layers are also GAD65-or CCK-positive, suggesting a GABAergic phenotype. On the other hand, TRPV1 is present in hippocampal pyramidal neurons 50 .
However, some studies point also to the occurrence of co-localization between both CB1 and TRPV1 receptors, thus indicating a more complex interaction 10, 19 .
In conclusion, our in vitro and in vivo data suggests the presence of a complex interaction between CB1, TRPV1, and TRKB culminating in a final balance between BDNF-dependent and independent signaling to induce or inhibit burying behavior, respectively. Regulation of the amount of BDNF released in the synaptic cleft would be an additional mechanism, beyond inherent receptor properties, by which CB1 and TRPV1 activation usually produce opposite effects. Therefore, endocannabinoids acting upon CB1 and TRPV1, could regulate the TRKB-dependent plasticity in both pre-and postsynaptic compartments of different neuronal populations in a coordinated manner. More studies, however, are required to investigate this possibility. Figure 6 . Graphical abstract for the interaction between CB1, TRPV1 and TRKB regulating burying behavior. The activation of CB1 by endocannabinoids (eCB) leads to TRKB coupling, activation and decrease in burying, putatively in GABAergic cells (dashed blue). On the other hand, the activation of TRPV1 receptors by eCB triggers the release of BDNF and activation of TRKB, possibly in pyramidal (dashed red) and/or neighbor cells (dashed green) leading to increase in burying.
